Clinical Management of Men with Nonobstructive Azoospermia due to Spermatogenic Failure

Achermann, Arnold Peter Paul; Esteves, Sandro C.

doi:10.1007/978-3-030-32300-4_23

Cited by 1 publication

(3 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This group shares similarities with Group 2 but differs by exhibiting reduced testosterone levels, indicating biochemical hypogonadism (1,7). Combining hCG with FSH may be beneficial in these patients as hCG boosts intratesticular testosterone production.…”

Section: Aphrodite Group 3: Biochemical Hypogonadismmentioning

confidence: 96%

“…Patients with reduced fertility and impaired spermatogenesis may face inadequate testicular stimulation due to deficits in FSH and/or LH production or action ( 5 ). Hypogonadism, characterized primarily by insufficient testosterone production, has various causes, including testicular pathologies, systemic diseases, infections, congenital abnormalities, aging, and poor lifestyle ( 7 ). In some instances, the underlying cause remains elusive, and hypogonadism is labeled idiopathic.…”

Section: Introductionmentioning

confidence: 99%

“…Group 4 primarily encompasses patients with nonobstructive azoospermia characterized by high FSH and low testosterone levels, indicating hypergonadotropic hypogonadism ( 7 ). These individuals have low testicular reserve, making them a challenge to treat ( 15 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Approaching treatment of male infertility: the APHRODITE criteria

Esteves,

Humaidan

2024

Int. braz j urol.

Self Cite

View full text Add to dashboard Cite

The Need for Improved ClassificationMale infertility is a complex clinical condition, and thus far, the clinical management of men with reduced fertility and impaired spermatogenesis has been fraught with difficulties and limited advancement (2). This has led to frustration among both clinicians and patients, perpetuating the belief that intracytoplasmic sperm injection (ICSI) is the only solution to provide the couple with a baby without the need to explore the nature or cause of the underlying male infertility (3, 4). The APHRODITE criteria aim to address this gap by providing a structured approach to characterize male infertility in men seeking paternity, particularly those who may benefit from hormonal treatment (1). Importantly, these criteria are not designed for men with established infertility diagnoses, such as varicocele, infection, or obstruction, who would not benefit from hormonal treatment (3). The Role of Hormones in SpermatogenesisUnderstanding the APHRODITE criteria begins with a brief review of human spermatogenesis, a complex process that takes approximately 75 days and is primarily controlled by follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-driven testosterone (5). These hormones are crucial in regulating spermatogenesis, making them central to our approach.

show abstract

Section: Aphrodite Group 3: Biochemical Hypogonadismmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%